Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    18465317 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Epirubicin, cyclophosphamide and docetaxel;   Drug: docetaxel, cyclophosphamide

Indicates status has not been verified in more than two years